Combination of radium-223 and enzalutamide benefits patients with mCRPC with bone metastases Presented ByProf. Silke Gillessen, Oncology Institute of Southern Switzerland TrialPhase 3, PEACE-3 ConferenceESMO 2024 TypePeer-reviewed article 4 November 2024 11:38